Fluspirilene NLT 98%

Fluspirilene is a non-competitive antagonist of L-type calcium channels with an IC₅₀ of 0.03 μM. Fluspirileneis a long-acting injectable depot antipsychotic drug used for schizophrenia. IC50 & Target: IC50: 0.03 μM (L-type calcium channel)^[1] In Vitro: Fluspirilene, at concentrations which non-competitively modify dihydropyridine binding, selectively antagonizes the effects of calcium-channel activators^[1]. Fluspirilene decreases the viability and suppresses sphere-forming of glioma stem cell lines in a dose-dependent manner. Fluspirilene demonstrates the inhibition of proliferation of T98, U87 and all GSC lines at 1.25, 2.5, and 5 μM, while it inhibits the proliferation of U251 and SNB19 at 2.5 and 5 μM^[2]. In Vivo: Mice treated with fluspirilene shows a remarkable reduction of the tumor size. Fluspirilene significantly prolongs survival of the TGS04 mouse model^[2].